<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03271268</url>
  </required_header>
  <id_info>
    <org_study_id>StLouisFrance</org_study_id>
    <nct_id>NCT03271268</nct_id>
  </id_info>
  <brief_title>Cardiovascular Biomarkers and Lung Edema in Severe Burns Patients</brief_title>
  <acronym>CAROLE</acronym>
  <official_title>The Role of CARdiovascular biOmarkers (NT-pro-BNP and CD146) in Predicting Lung Edema in Severely Burned Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint-Louis Hospital, Paris, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint-Louis Hospital, Paris, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Burn injury leads to hypovolemic then distributive shock. Fluid resuscitation remains the
      cornerstone of initial treatment of burn shock. However, fluid rescucitation can lead to
      fluid overload, which manifests most notably as lung edema.

      The peptide NT-pro-BNP, a biomarker of cardiac congestion secreted by the myocardium, as well
      as plasma CD146, an endothelial factor involved in angiogenesis and a marker of vascular
      congestion, may help identifying patients with risk of pulmonary edema and hypoxia .

      Our hypothesis is that these biomarkers may predict the occurence of pulmonary edema in
      severe burns patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2017</start_date>
  <completion_date type="Anticipated">April 6, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 6, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lung edema</measure>
    <time_frame>During the first 7 days of admission</time_frame>
    <description>Extravascular lung water (EVLW) &gt; 10 mL/Kg as measured by transpulmonary thermodilution (TPTD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoxemia</measure>
    <time_frame>During the first 7 days of admission for mechanically-ventilated patients</time_frame>
    <description>PaO2/FiO2 ratio of &lt;200</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypercapnia</measure>
    <time_frame>During the first 7 days of admission for mechanically-ventilated patients</time_frame>
    <description>PaCO2&gt; 45 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected minute ventilation &gt; 10L/min</measure>
    <time_frame>During the first 7 days of admission for mechanically-ventilated patients</time_frame>
    <description>Minute ventilation × partial [Paco2]/40) &gt; 10L/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple organ dysfunction syndrome (MODS)</measure>
    <time_frame>During the first 7 days of admission</time_frame>
    <description>Sequential Organ Failure Assessment score (SOFA) ≥ 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the ICU</measure>
    <time_frame>until 90 days of hospitalization</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Burns</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum bank : 1 sample (5 ml of blood): on admission and from day 1 to day 7 of admission.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Severely ill burn patients admitted to a tertiary referral burn center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intubated mechanically-ventilated patients within the first 24 hours of admission

          -  And/or patients with total body surface area (TBSA) burn-injured &gt;20 %

          -  And/or patients with at least 10% full-thickness burns

          -  And/or receiving vasopressors within the first 24 hours of admission

          -  And monitored by a PiCCO system (PiCCO-2 Pulsion Medical Systems AG, Munich, Germany)

        Exclusion Criteria:

          -  Admission delay to ICU &gt; 24 hours post burn

          -  Age less than 18 years

          -  Pregnancy

          -  Chronic renal impairment with a baseline eGFR &lt; 15 ml/min

          -  Patients with chemical or electrical burns

          -  Coexisting non-burn trauma

          -  Patients moribund on admission or dead within 72 h from admission

          -  Patients with do-not-resuscitate orders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabri Soussi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint-Louis Hospital, Paris, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabri Soussi, MD</last_name>
    <phone>0613064542</phone>
    <phone_ext>+33</phone_ext>
    <email>sabri.soussi@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthieu Legrand, MD, PhD</last_name>
    <phone>0685104235</phone>
    <phone_ext>+33</phone_ext>
    <email>matthieu.m.legrand@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sabri SOUSSI</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabri Soussi, MD</last_name>
      <phone>0613064542</phone>
      <phone_ext>+33</phone_ext>
      <email>sabri.soussi@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Matthieu Legrand, MD, PhD</last_name>
      <phone>0685104235</phone>
      <phone_ext>+33</phone_ext>
      <email>matthieu.m.legrand@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/?term=Soluble+CD146%2C+a+new+endothelial+biomarker+of+acutely+decompensated+heart+failure</url>
    <description>Soluble CD146, a new endothelial biomarker of acutely decompensated heart failure</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/23425748</url>
    <description>Natriuretic peptide type B in burn intensive care</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/?term=Plasma+Levels+of+Soluble+CD146+Reflect+the+Severity+of+Pulmonary+Congestion+Better+Than+Brain+Natriuretic+Peptide+in+Acute+Coronary+Syndrome</url>
    <description>Plasma Levels of Soluble CD146 Reflect the Severity of Pulmonary Congestion Better Than Brain Natriuretic Peptide in Acute Coronary Syndrome</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2017</study_first_submitted>
  <study_first_submitted_qc>August 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2017</study_first_posted>
  <last_update_submitted>September 4, 2017</last_update_submitted>
  <last_update_submitted_qc>September 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint-Louis Hospital, Paris, France</investigator_affiliation>
    <investigator_full_name>Sabri SOUSSI</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Vascular filling</keyword>
  <keyword>Fluid overload</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Lung edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

